Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment

Diabetic Medicine

Volumn 32, Issue 3, 2015, Pages 343-352

  von Scholten, B J ^a   Lajer, M ^a   Goetze, J P ^b,c   Persson, F ^a   Rossing, P ^a,c,d  

^a STENO DIABETES CENTER   (Denmark)

^b Rigshospitalet   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTIHYPERTENSIVE AGENT; ATRIAL NATRIURETIC FACTOR; CREATININE; LIRAGLUTIDE; SODIUM; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTERIAL STIFFNESS; ARTICLE; CLINICAL ARTICLE; CREATININE URINE LEVEL; EXTRACELLULAR SPACE; FEMALE; HEART RATE; HUMAN; HYPERTENSION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM URINE LEVEL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; AGONISTS; ALBUMINURIA; BLOOD PRESSURE; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DRUG EFFECTS; GLOMERULUS FILTRATION RATE; INCIDENCE; KIDNEY; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; TIME; TREATMENT OUTCOME; URINE;

ADULT; AGED; ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLOMERULAR FILTRATION RATE; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HEART RATE; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; INCIDENCE; KIDNEY; LIRAGLUTIDE; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME;

EID: 84922572669     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12594     Document Type: Article

References (37)

1. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007; 87: 1409-1439.
2. Marre M, Shaw J, Brandle M, Bebakar WM, Kamaruddin NA, Strand J et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009; 26: 268-278.
3. Vilsboll T, Garber AJ. Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide. Diabetes Obes Metab 2012; 14(Suppl 2): 41-49.
4. Bode B. An overview of the pharmacokinetics, efficacy and safety of liraglutide. Diabetes Res Clin Pract 2012; 97: 27-42.
5. Fonseca V, Madsbad S, Falahati A. Once-daily human GLP-1 analog liraglutide reduces systolic BP: a meta-analysis of 6 clinical trials. Diabetes 2009; 58 (Suppl. 1) Abstract545-P.
6. Gallwitz B, Vaag A, Falahati A, Madsbad S. Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time. Int J Clin Pract 2010; 64: 267-276.
7. Gutzwiller JP, Tschopp S, Bock A, Zehnder CE, Huber AR, Kreyenbuehl M et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 2004; 89: 3055-3061.
8. Kim M, Platt MJ, Shibasaki T, Quaggin SE, Backx PH, Seino S et al. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med 2013; 19: 567-575.
9. Nair D, Tan SY, Gan HW, Lim SF, Tan J, Zhu M et al. The use of ambulatory tonometric radial arterial wave capture to measure ambulatory blood pressure: the validation of a novel wrist-bound device in adults. J Hum Hypertens 2008; 22: 220-222.
10. Theilade S, Joergensen C, Persson F, Lajer M, Rossing P. Ambulatory tonometric blood pressure measurements in patients with diabetes. Diabetes Technol Ther 2012; 14: 453-456.
11. Brochner-Mortensen J. A simple method for the determination of glomerular filtration rate. Scand J Clin Lab Invest 1972; 30: 271-274.
12. Morgenthaler NG, Struck J, Thomas B, Bergmann A. Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem 2004; 50: 234-236.
13. Hunter I, Alehagen U, Dahlstrom U, Rehfeld JF, Crimmins DL, Goetze JP. N-Terminal pro-atrial natriuretic peptide measurement in plasma suggests covalent modification. Clin Chem 2011; 57: 1327-1330.
14. Franklin SS, Larson MG, Khan SA, Wong ND, Leip EP, Kannel WB et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001; 103: 1245-1249.
15. Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez ME et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 2002; 110: 43-52.
16. Fonseca V, Falahati A, Zychma M. A meta-analysis of six clinical trials demonstrates that the once-daily human GLP-1 analogue liraglutide reduces systolic blood pressure. Diabetologia 2009 [Abstract].
17. Okerson T, Yan P, Stonehouse A, Brodows R. Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. Am J Hypertens 2010; 23: 334-339.
18. Robinson LE, Holt TA, Rees K, Randeva HS, O'Hare JP. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open 2013; 3: e001986.
19. Pyke C, Heller RS, Kirk RK, Orskov C, Reedtz-Runge S, Kaastrup P et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 2014; 155: 1280-1290.
20. Ramirez G, Saba SR, Dietz JR, Vesely DL. Immunocytochemical localization of proANF 1-30, proANF 31-67 and atrial natriuretic factor in the kidney. Kidney Int 1992; 41: 334-341.
21. Olsen MH, Wachtell K, Tuxen C, Fossum E, Bang LE, Hall C et al. Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: a LIFE substudy. J Hypertens 2005; 23: 1083-1090.
22. Kohno M, Yokokawa K, Yasunari K, Kano H, Minami M, Hanehira T et al. Changes in plasma cardiac natriuretic peptides concentrations during 1 year treatment with angiotensin-converting enzyme inhibitor in elderly hypertensive patients with left ventricular hypertrophy. Int J Clin Pharmacol Ther 1997; 35: 38-42.
23. Bernardi S, Burns WC, Toffoli B, Pickering R, Sakoda M, Tsorotes D et al. Angiotensin-converting enzyme 2 regulates renal atrial natriuretic peptide through angiotensin-(1-7). Clin Sci (Lond) 2012; 123: 29-37.
24. Skov J, Holst JJ, Gotze JP, Frokiaer J, Christiansen JS. Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males. Endocr Connect 2014; 3: 11-16.
25. van Hateren KJ, Landman GW, Kleefstra N, Groenier KH, Struck J, Navis GJ et al. The midregional fragment of pro-A-type natriuretic peptide, blood pressure, and mortality in a prospective cohort study of patients with type 2 diabetes (ZODIAC-25). Diabetes Care 2013; 36: 1347-1352.
26. Christiansen JS, Frandsen M, Parving HH. Effect of intravenous glucose infusion on renal function in normal man and in insulin-dependent diabetics. Diabetologia 1981; 21: 368-373.
27. Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014; 129: 587-597.
28. Imamura S, Hirai K, Hirai A. The glucagon-like peptide-1 receptor agonist, liraglutide, attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients. Tohoku J Exp Med 2013; 231: 57-61.
29. Bergenstal RM, Wysham C, Macconell L, Malloy J, Walsh B, Yan P et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010; 376: 431-439.
30. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-1326.
31. Zhang H, Zhang X, Hu C, Lu W. Exenatide reduces urinary transforming growth factor-beta1 and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria. Kidney Blood Press Res 2012; 35: 483-488.
32. Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364: 907-917.
33. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
34. de ZD, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110: 921-927.
35. Rossing P, Hommel E, Smidt UM, Parving HH. Reduction in albuminuria predicts diminished progression in diabetic nephropathy. Kidney Int Suppl 1994; 45: S145-S149.
36. Skov J, Dejgaard A, Frokiaer J, Holst JJ, Jonassen T, Rittig S et al. Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men. J Clin Endocrinol Metab 2013; 98: E664-E671.
37. Mima A, Hiraoka-Yamomoto J, Li Q, Kitada M, Li C, Geraldes P et al. Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCbeta activation in diabetes. Diabetes 2012; 61: 2967-2979.